Lyra Therapeutics, Inc.
LYRA
$0.0873
$0.00080.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 7.18% | -67.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.18% | -67.39% | |||
| Cost of Revenue | 7.79% | -55.50% | |||
| Gross Profit | -7.81% | 54.94% | |||
| SG&A Expenses | -8.09% | -23.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.44% | -46.57% | |||
| Operating Income | -1.33% | 45.87% | |||
| Income Before Tax | 7.53% | 75.34% | |||
| Income Tax Expenses | -14.29% | -41.67% | |||
| Earnings from Continuing Operations | 7.53% | 75.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.53% | 75.33% | |||
| EBIT | -1.33% | 45.87% | |||
| EBITDA | -0.17% | 45.65% | |||
| EPS Basic | 7.61% | 75.33% | |||
| Normalized Basic EPS | -2.89% | 46.54% | |||
| EPS Diluted | 7.61% | 75.33% | |||
| Normalized Diluted EPS | -2.89% | 46.54% | |||
| Average Basic Shares Outstanding | 0.08% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||